Analysts Set STAAR Surgical (STAA) Price Target at $43.33

Shares of STAAR Surgical (NASDAQ:STAA) have been assigned a consensus recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $43.33.

Several brokerages have recently issued reports on STAA. ValuEngine cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research cut STAAR Surgical from a “buy” rating to a “hold” rating in a research note on Saturday, March 2nd. Finally, BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th.

Shares of NASDAQ STAA traded down $0.91 during mid-day trading on Tuesday, hitting $31.21. The company had a trading volume of 498,646 shares, compared to its average volume of 385,228. The stock has a market cap of $1.38 billion, a P/E ratio of 111.46 and a beta of 2.10. STAAR Surgical has a 1-year low of $15.30 and a 1-year high of $54.00.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Thursday, February 21st. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.01. The business had revenue of $31.19 million for the quarter, compared to analysts’ expectations of $31.20 million. STAAR Surgical had a return on equity of 13.86% and a net margin of 4.01%. As a group, sell-side analysts expect that STAAR Surgical will post 0.3 earnings per share for the current fiscal year.

In other STAAR Surgical news, insider Samuel J. Gesten sold 1,500 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $36.20, for a total value of $54,300.00. Following the sale, the insider now directly owns 36,816 shares in the company, valued at $1,332,739.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Samuel J. Gesten sold 1,688 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $38.87, for a total value of $65,612.56. Following the completion of the sale, the insider now owns 36,816 shares in the company, valued at $1,431,037.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,730 shares of company stock worth $655,538. 3.90% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of STAA. Strs Ohio grew its holdings in shares of STAAR Surgical by 1.2% during the fourth quarter. Strs Ohio now owns 24,800 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 300 shares during the last quarter. AdvisorNet Financial Inc grew its holdings in shares of STAAR Surgical by 600.0% during the fourth quarter. AdvisorNet Financial Inc now owns 875 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 750 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of STAAR Surgical by 12.7% during the fourth quarter. Legal & General Group Plc now owns 7,616 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 857 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of STAAR Surgical by 0.5% during the fourth quarter. American Century Companies Inc. now owns 175,398 shares of the medical instruments supplier’s stock worth $5,597,000 after purchasing an additional 892 shares during the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in shares of STAAR Surgical by 3.2% during the fourth quarter. Chartwell Investment Partners LLC now owns 36,161 shares of the medical instruments supplier’s stock worth $1,154,000 after purchasing an additional 1,122 shares during the last quarter. Institutional investors own 89.92% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Further Reading: What are no-load funds?

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.